TickerStat.comEloxx Pharmaceuticals annual r&d spending
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals R&D Spending Growth & History (ELOX)
Eloxx Pharmaceuticals's r&d spending was $3.1M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.1M | −$521,000 | −14.57% |
| 2024 | 2024-12-31 | $3.6M | −$5.0M | −58.40% |
| 2023 | 2023-12-31 | $8.6M | −$15.1M | −63.76% |
| 2022 | 2022-12-31 | $23.7M | $828,000 | +3.62% |
| 2021 | 2021-12-31 | $22.9M | $8.3M | +56.95% |
| 2020 | 2020-12-31 | $14.6M | −$11.8M | −44.63% |
| 2019 | 2019-12-31 | $26.3M | $5.9M | +28.60% |
| 2018 | 2018-12-31 | $20.5M | $4.1M | +24.95% |
| 2017 · Dec 31 | 2017-12-31 | $16.4M | $7.4M | +82.48% |
| 2017 · Jun 30 | 2017-06-30 | $733,661 | −$1.4M | −66.39% |
| 2016 · Dec 31 | 2016-12-31 | $9.0M | $3.1M | +53.82% |
| 2016 · Jun 30 | 2016-06-30 | $2.2M | −$2.4M | −52.22% |
| 2015 · Dec 31 | 2015-12-31 | $5.8M | — | — |
| 2015 · Jun 30 | 2015-06-30 | $4.6M | $1.2M | +36.83% |
| 2014 | 2014-06-30 | $3.3M | $1.3M | +60.00% |
| 2013 | 2013-06-30 | $2.1M | −$479,581 | −18.69% |
| 2012 | 2012-06-30 | $2.6M | −$1.2M | −31.02% |
| 2011 | 2011-06-30 | $3.7M | $1.1M | +41.06% |
| 2010 | 2010-06-30 | $2.6M | — | — |
Eloxx Pharmaceuticals quarterly r&d spending
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.8M | $1.9M | +216.26% |
| Q1 2026 | 2026-03-31 | $1.7M | $1.1M | +225.29% |
| Q2 2025 | 2025-06-30 | $898,000 | — | — |
| Q1 2025 | 2025-03-31 | $510,000 | — | — |
| Q4 2023 | 2023-12-31 | $1.5M | −$1.8M | −53.84% |
| Q3 2023 | 2023-09-30 | $1.3M | −$3.6M | −74.39% |
| Q2 2023 | 2023-06-30 | $2.3M | −$5.3M | −69.44% |
| Q1 2023 | 2023-03-31 | $3.5M | −$4.4M | −55.84% |
| Q4 2022 | 2022-12-31 | $3.3M | −$4.6M | −58.33% |
| Q3 2022 | 2022-09-30 | $4.9M | −$330,000 | −6.33% |
| Q2 2022 | 2022-06-30 | $7.7M | $1.9M | +34.13% |
| Q1 2022 | 2022-03-31 | $7.9M | $3.8M | +93.94% |
| Q4 2021 | 2021-12-31 | $7.9M | $5.3M | +199.70% |
| Q3 2021 | 2021-09-30 | $5.2M | $1.8M | +51.23% |
| Q2 2021 | 2021-06-30 | $5.7M | $2.0M | +52.59% |
| Q1 2021 | 2021-03-31 | $4.1M | −$694,000 | −14.56% |
| Q4 2020 | 2020-12-31 | $2.6M | −$3.5M | −57.34% |
| Q3 2020 | 2020-09-30 | $3.4M | −$3.4M | −49.35% |
| Q2 2020 | 2020-06-30 | $3.7M | −$3.6M | −49.07% |
| Q1 2020 | 2020-03-31 | $4.8M | −$1.3M | −20.80% |
| Q4 2019 | 2019-12-31 | $6.2M | −$341,000 | −5.22% |
| Q3 2019 | 2019-09-30 | $6.8M | $1.4M | +25.60% |
| Q2 2019 | 2019-06-30 | $7.3M | $3.2M | +76.87% |
| Q1 2019 | 2019-03-31 | $6.0M | $1.6M | +36.98% |
| Q4 2018 | 2018-12-31 | $6.5M | −$1.9M | −22.26% |
| Q3 2018 | 2018-09-30 | $5.4M | $2.1M | +65.09% |
| Q2 2018 | 2018-06-30 | $4.2M | $1.6M | +59.92% |
| Q1 2018 · Mar 31 | 2018-03-31 | $4.4M | $2.0M | +86.58% |
| Q4 2017 | 2017-12-31 | $8.4M | $8.2M | +3950.61% |
| Q1 2018 · Sep 30 | 2017-09-30 | $3.3M | $3.0M | +1070.43% |
| Q4 2017 | 2017-06-30 | $2.6M | $2.2M | +532.22% |
| Q1 2017 · Mar 31 | 2017-03-31 | $2.4M | $1.8M | +308.54% |
| Q4 2016 | 2016-12-31 | $207,376 | −$387,128 | −65.12% |
| Q1 2017 · Sep 30 | 2016-09-30 | $280,240 | −$321,343 | −53.42% |
| Q4 2016 | 2016-06-30 | $410,459 | −$430,635 | −51.20% |
| Q1 2016 · Mar 31 | 2016-03-31 | $576,443 | $341,188 | +145.03% |
| Q4 2015 | 2015-12-31 | $594,504 | −$777,426 | −56.67% |
| Q1 2016 · Sep 30 | 2015-09-30 | $601,583 | −$1.5M | −71.63% |
| Q4 2015 | 2015-06-30 | $841,094 | $10,505 | +1.26% |
| Q3 2015 | 2015-03-31 | $235,255 | −$731,089 | −75.66% |
| Q2 2015 | 2014-12-31 | $1.4M | $641,113 | +87.73% |
| Q1 2015 | 2014-09-30 | $2.1M | $1.3M | +161.45% |
| Q4 2014 | 2014-06-30 | $830,589 | $341,285 | +69.75% |
| Q3 2014 | 2014-03-31 | $966,344 | $473,494 | +96.07% |
| Q2 2014 | 2013-12-31 | $730,817 | $139,738 | +23.64% |
| Q1 2014 | 2013-09-30 | $810,937 | $297,504 | +57.94% |
| Q4 2013 | 2013-06-30 | $489,304 | −$150,451 | −23.52% |
| Q3 2013 | 2013-03-31 | $492,850 | −$47,939 | −8.86% |
| Q2 2013 | 2012-12-31 | $591,079 | −$160,438 | −21.35% |
| Q1 2013 | 2012-09-30 | $513,433 | −$120,753 | −19.04% |
| Q4 2012 | 2012-06-30 | $639,755 | $54,561 | +9.32% |
| Q3 2012 | 2012-03-31 | $540,789 | −$259,552 | −32.43% |
| Q2 2012 | 2011-12-31 | $751,517 | −$46,835 | −5.87% |
| Q1 2012 | 2011-09-30 | $634,186 | −$902,321 | −58.73% |
| Q4 2011 | 2011-06-30 | $585,194 | — | — |
| Q3 2011 | 2011-03-31 | $800,341 | — | — |
| Q2 2011 | 2010-12-31 | $798,352 | — | — |
| Q1 2011 | 2010-09-30 | $1.5M | — | — |
Eloxx Pharmaceuticals r&d spending trends
Over the last five fiscal years, Eloxx Pharmaceuticals's r&d spending decreased from $14.6M to $3.1M, a change of −$11.5M. The latest reported quarter, Q2 2026, shows $2.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...